Literature DB >> 8203850

Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.

R Mizukane1, Y Hirakata, M Kaku, Y Ishii, N Furuya, K Ishida, H Koga, S Kohno, K Yamaguchi.   

Abstract

The inhibitory effects of azithromycin (AZM), a new 15-membered macrolide antibiotic, on the production of exotoxin A, total protease, elastase, and phospholipase C by Pseudomonas aeruginosa were determined, and the virulence-suppressing effects of AZM were compared with those of erythromycin (EM), roxithromycin (RXM), and rokitamycin (RKM). The effect of exposure of P. aeruginosa PA103 or B16 in cultures to sub-MICs of these macrolide antibiotics on the production of exoenzymes was determined. AZM suppressed the in vitro production of extracellular and intracellular exotoxin A by P. aeruginosa PA103 more than did EM, even at a concentration of only 2 micrograms/ml. At concentrations of between 4 and 32 micrograms/ml, AZM also inhibited total protease, elastase, and phospholipase C production by P. aeruginosa B16 more than did EM, RXM, and RKM. AZM was effective in suppressing exotoxin A and total protease production through 24 h of incubation in the presence of drug at sub-MICs, but it had no significant effect on either the growth of P. aeruginosa or its total protein production. Moreover, at a concentration of 4 micrograms/ml, AZM suppressed exoenzyme production by other strains of P. aeruginosa more than did EM. These findings indicate that AZM, EM, RXM, and RKM each has an inhibitory effect on exoenzyme production separate from the antimicrobial effect and that, of these macrolides, AZM has the strongest virulence-suppressing effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203850      PMCID: PMC284493          DOI: 10.1128/AAC.38.3.528

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  35 in total

1.  Photometric method for estimation of elastase activity.

Authors:  L A SACHAR; K K WINTER; N SICHER; S FRANKEL
Journal:  Proc Soc Exp Biol Med       Date:  1955-11

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo.

Authors:  P V Liu
Journal:  J Infect Dis       Date:  1966-10       Impact factor: 5.226

4.  Studies of phospholipase C (heat-labile hemolysin) in Pseudomonas aeruginosa.

Authors:  R M Berka; G L Gray; M L Vasil
Journal:  Infect Immun       Date:  1981-12       Impact factor: 3.441

5.  Diffuse panbronchiolitis. A disease of the transitional zone of the lung.

Authors:  H Homma; A Yamanaka; S Tanimoto; M Tamura; Y Chijimatsu; S Kira; T Izumi
Journal:  Chest       Date:  1983-01       Impact factor: 9.410

6.  Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection.

Authors:  M Pollack; L T Callahan; N S Taylor
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

7.  Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.

Authors:  K Snell; I A Holder; S A Leppla; C B Saelinger
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

8.  Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats.

Authors:  D E Woods; S J Cryz; R L Friedman; B H Iglewski
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Toxin A-deficient mutants of Pseudomonas aeruginosa PA103: isolation and characterization.

Authors:  D E Ohman; J C Sadoff; B H Iglewski
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

10.  Evaluation of Pseudomonas aeruginosa exotoxin A and elastase as virulence factors in acute lung infection.

Authors:  L L Blackwood; R M Stone; B H Iglewski; J E Pennington
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.609

View more
  19 in total

1.  Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.

Authors:  K Tateda; R Comte; J C Pechere; T Köhler; K Yamaguchi; C Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Therapeutic frontiers: preventing and treating infectious diseases by inhibiting bacterial quorum sensing.

Authors:  C A Martin; A D Hoven; A M Cook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-03-06       Impact factor: 3.267

4.  Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin.

Authors:  K Tateda; Y Ishii; T Matsumoto; N Furuya; M Nagashima; T Matsunaga; A Ohno; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 5.  Exploiting quorum sensing to confuse bacterial pathogens.

Authors:  Breah LaSarre; Michael J Federle
Journal:  Microbiol Mol Biol Rev       Date:  2013-03       Impact factor: 11.056

Review 6.  Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis.

Authors:  P M Bartold; A H du Bois; S Gannon; D R Haynes; R S Hirsch
Journal:  Inflammopharmacology       Date:  2013-02-28       Impact factor: 4.473

Review 7.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

8.  Azithromycin inhibits expression of the GacA-dependent small RNAs RsmY and RsmZ in Pseudomonas aeruginosa.

Authors:  Isabel Pérez-Martínez; Dieter Haas
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

Review 9.  Macrolide antibiotics for cystic fibrosis.

Authors:  Kevin W Southern; Pierre M Barker; Arturo Solis-Moya; Latifa Patel
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

10.  Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.

Authors:  Nadine Hoffmann; Baoleri Lee; Morten Hentzer; Thomas Bovbjerg Rasmussen; Zhijun Song; Helle Krogh Johansen; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.